MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cerulean Pharma Company Profile (NASDAQ:CERU)

Consensus Ratings for Cerulean Pharma (NASDAQ:CERU) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (383.09% upside)

Analysts' Ratings History for Cerulean Pharma (NASDAQ:CERU)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016WedbushReiterated RatingOutperform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2016Leerink SwannReiterated RatingOutperform$10.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Boost Price TargetMarket Outperform$9.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016BarclaysLower Price TargetOverweight$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Cerulean Pharma (NASDAQ:CERU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.43)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015($0.36)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.32)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.36)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/29/2014($3.52)($3.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cerulean Pharma (NASDAQ:CERU)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.38)($0.40)
Q2 20162($0.49)($0.48)($0.49)
Q3 20162($0.50)($0.37)($0.44)
Q4 20162($0.52)($0.38)($0.45)
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)
Dividend History for Cerulean Pharma (NASDAQ:CERU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cerulean Pharma (NASDAQ:CERU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cerulean Pharma (NASDAQ:CERU)
DateHeadline
06/23/16 04:38 PMNew Broker Ratings For Cerulean Pharma Inc. (CERU) - FTSE News
06/23/16 10:55 AMCerulean Pharma : Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
06/23/16 06:19 AMCerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors - [at noodls] - WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the ...
06/22/16 08:29 AMCerulean Announces Publication in Cancer Research - [at noodls] - Paper Highlights Preclinical Proof of Concept of CRLX101 in Combination with Avastin (bevacizumab) in Models of Metastatic Triple-Negative Breast Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma ...
06/19/16 03:01 PMCerulean Pharma Inc. (CERU) Analyst Price Targets For The Coming Week - Fiscal Standard
06/15/16 03:14 PMBiotechnology Volatile Stocks: ImmunoGen, Inc. (NASDAQ:IMGN), Cerulean Pharma Inc. (NASDAQ:CERU), Eleven ... - KC Register
06/14/16 06:09 AMCerulean to Present at JMP Securities Life Sciences Conference - [at noodls] - WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President ...
06/10/16 04:03 PMCerulean Pharma, Inc. :CERU-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/09/16 06:19 AMCerulean Announces Manuscript Published in Annals of Oncology - [at noodls] - Data from 22 Evaluable Metastatic Renal Cell Carcinoma Patients Treated with CRLX101 in Combination with Avastin® in Phase 1b/2 Investigator-Sponsored Trial Led by University of Pennsylvania WALTHAM, Mass.--(BUSINESS ...
06/05/16 08:28 PMAre Analysts Bullish Cerulean Pharma Inc (NASDAQ:CERU) After Last Week? - HNN
06/02/16 09:14 PMCerulean Pharma Inc (CERU) Research Coverage Started at Janney Montgomery Scott - Let Me Know About This - Cerulean Pharma Inc (CERU) Research Coverage Started at Janney Montgomery ScottLet Me Know About ThisCerulean Pharma logo Analysts at Janney Montgomery Scott began coverage on shares of Cerulean Pharma Inc (NASDAQ:CERU) in a research report issued on Wednesday, StockTargetPrices.com reports. The brokerage set a “buy” rating on the stock.
06/01/16 03:15 PMNews Sentiment For Cerulean Pharma Inc. (NASDAQ:CERU) - Investor Newswire - News Sentiment For Cerulean Pharma Inc. (NASDAQ:CERU)Investor NewswireCerulean Pharma Inc. has a 0 in the recent session. By this score, sell-side analysts examining the equity, have given a 13-month price estimate of $8 on the stock. It is arrived at by taking into account the stock recommendations of 5 analysts. These ...and more »
06/01/16 11:43 AMCerulean Pharma Inc. (NASDAQ:CERU) Stock Update & Estimates - Stock Tick Tock - Cerulean Pharma Inc. (NASDAQ:CERU) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Cerulean Pharma Inc. (NASDAQ:CERU) to post earnings of $-0.48 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...Share Rating Focus on Cerulean Pharma Inc. (NASDAQ:CERU)HNNall 2 news articles »
05/31/16 03:10 PMShare Rating Focus on Cerulean Pharma Inc. (NASDAQ:CERU) - HNN - Share Rating Focus on Cerulean Pharma Inc. (NASDAQ:CERU)HNNPresently, Wall Street analysts have given a consensus stock rating of 1 on shares of Cerulean Pharma Inc. (NASDAQ:CERU). Covering analysts will typically provide Buy, Sell, or Hold recommendations based on extensive research. This consensus number ...and more »
05/29/16 07:43 PMForm 4 Cerulean Pharma Inc. For: Jan 05 Filed by: ONeill James E - StreetInsider.com - Form 4 Cerulean Pharma Inc. For: Jan 05 Filed by: ONeill James EStreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. FORM 4, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. STATEMENT OF CHANGES IN BENEFICIAL ...and more »
05/27/16 08:57 PMCERULEAN PHARMA INC. : Change in Directors or Principal Officers (form 8-K) - 05/02 CERULEAN PHARMA INC.: Results of Operations and Financial Condition, Financial .. 05/02 CERULEAN PHARMA: Reports First Quarter 2016 Corporate Highlights and Financial .. 04/25 CERULEAN PHARMA: Announces Oral Presentation of CRLX101 Clinical Data at ...
05/27/16 08:57 PMForm 4 Cerulean Pharma Inc. For: Dec 31 Filed by: ONeill James E - Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute ...
05/27/16 03:27 PMCERULEAN PHARMA INC. Files SEC form 8-K, Change in Directors or Principal Officers -
05/25/16 07:43 PM2016 Gastric Cancer Pipeline Market Covering 127 Companies - z o.o., Cerulean Pharma, Inc., Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co., Ltd., Compliment Corporation, Curaxys, S.L., DAE HWA Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Deciphera Pharmaceuticals, LLC, Dr. Reddy's Laboratories ...
05/20/16 01:17 AMCerulean Pharma : Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the Company will present in an oral session Phase 1b results of an ongoing clinical trial of CRLX101 in combination with ...
05/20/16 01:17 AMCerulean Pharma (CERU) to Present at ASCO - Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster ...
05/18/16 08:12 PMRevenue Update on Cerulean Pharma Inc(NASDAQ:CERU) - Trade Calls - Revenue Update on Cerulean Pharma Inc(NASDAQ:CERU)Trade CallsCerulean Pharma Inc(NASDAQ:CERU) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 2, 2016. Earnings per share were $-0.49. Analysts had estimated an EPS of $-0.43. In a different note, On Mar ...Latest Analyst Ratings For Cerulean Pharma Inc. (CERU)Share Trading Newsall 3 news articles »
05/18/16 05:12 PMCerulean to Present at the 2016 ASCO Annual Meeting - [at noodls] - WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced a scheduled poster presentation on CRLX301 at the ...
05/12/16 09:28 PMCerulean Pharma (CERU) Commences Dosing in CRLX101 + LYNPARZA Phase 1/2 - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Cerulean Pharma Inc. (Nasdaq: CERU) announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate ...
05/10/16 08:28 PMConsensus Rating Review for Cerulean Pharma Inc. (NASDAQ:CERU) - B.O.D.Y Confidential - Consensus Rating Review for Cerulean Pharma Inc. (NASDAQ:CERU)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Cerulean Pharma Inc. (NASDAQ:CERU). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or ...and more »
05/10/16 06:38 AMCerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA™ - [at noodls] - Trial Conducted in Collaboration with the National Cancer Institute and AstraZeneca WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug ...
05/08/16 10:30 PMNext Weeks Broker Price Targets For Cerulean Pharma Inc. (CERU) - Share Trading News - Next Weeks Broker Price Targets For Cerulean Pharma Inc. (CERU)Share Trading News03/11/2016 – Cerulean Pharma Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 8 price target on the stock. 01/05/2016 – Janney Montgomery Scott began new coverage on Cerulean Pharma Inc. giving the ...and more »
05/07/16 12:04 PMCERULEAN PHARMA INC. Financials -
05/05/16 09:22 PMEarnings Outlook on Cerulean Pharma Inc. (NASDAQ:CERU) - B.O.D.Y Confidential - Earnings Outlook on Cerulean Pharma Inc. (NASDAQ:CERU)B.O.D.Y ConfidentialAnalysts and investors will be anticipating Cerulean Pharma Inc. (NASDAQ:CERU)'s next earnings release which is expected to be posted on or around 2016-08-04. Sell-side research firms on Wall Street are expecting that the company will post EPS of ...and more »
05/05/16 09:22 PMBroker Roundup For Cerulean Pharma Inc. (CERU) - Share Trading News - Broker Roundup For Cerulean Pharma Inc. (CERU)Share Trading News03/11/2016 – Cerulean Pharma Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 8 price target on the stock. 01/05/2016 – Janney Montgomery Scott began new coverage on Cerulean Pharma Inc. giving the ...Cerulean Pharma Incorporated (NASDAQ:CERU) Shorts Decreased by 10.12% After Short CoveringFranklin Independentall 3 news articles »
05/04/16 09:07 PMAverage Analyst Rating for Cerulean Pharma Inc. (NASDAQ:CERU) - B.O.D.Y Confidential - Average Analyst Rating for Cerulean Pharma Inc. (NASDAQ:CERU)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Cerulean Pharma Inc. (NASDAQ:CERU) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 10:13 PMEdited Transcript of CERU earnings conference call or presentation 2-May-16 8:30pm GMT -
05/02/16 04:31 PMCerulean reports 1Q loss -
05/02/16 03:30 PMCerulean Reports First Quarter 2016 Corporate Highlights and Financial Results - [at noodls] - Conference Call Today at 4:30 p.m. ET WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today provided an update ...
05/02/16 03:14 PMCERULEAN PHARMA INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi -
05/02/16 03:04 PMCERULEAN PHARMA INC. Files SEC form 10-Q, Quarterly Report -
05/02/16 06:07 AMQ1 2016 Cerulean Pharma Inc Earnings Release - Time Not Supplied -
05/02/16 03:36 AMThis Weeks Broker Price Targets For Cerulean Pharma Inc. (CERU) - Share Trading News - This Weeks Broker Price Targets For Cerulean Pharma Inc. (CERU)Share Trading News03/11/2016 – Cerulean Pharma Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 8 price target on the stock. 01/05/2016 – Janney Montgomery Scott began new coverage on Cerulean Pharma Inc. giving the ...
04/27/16 09:12 PMCerulean Pharma Inc. (NASDAQ:CERU) Wall Street Rating in Focus - News Tribune - Cerulean Pharma Inc. (NASDAQ:CERU) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 5 equity research firms that cover shares of Cerulean Pharma Inc. (NASDAQ:CERU).and more »
04/27/16 05:09 AMCerulean Pharma (CERU) to Present CRLX101 Data at Gynecologic Oncology Conference - StreetInsider.com - Cerulean Pharma (CERU) to Present CRLX101 Data at Gynecologic Oncology ConferenceStreetInsider.comCerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Carolyn N. Krasner, M.D., of the Massachusetts General Hospital Cancer Center, will give an oral presentation on the ...Cerulean Pharma Shares Slip 2%; Ovarian Cancer Drug CRLX101 'Well Tolerated' in Phase 1b Trial (NASDAQ:CERU)Sonoran Weekly Reviewall 4 news articles »
04/26/16 07:52 PMCerulean Pharma Inc. (NASDAQ:CERU) Share Rating Recap - B.O.D.Y Confidential - Cerulean Pharma Inc. (NASDAQ:CERU) Share Rating RecapB.O.D.Y ConfidentialShares of Cerulean Pharma Inc. (NASDAQ:CERU) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...
04/26/16 12:08 AMCerulean Pharma : to Host First Quarter 2016 Conference Call on May 2 - Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the first quarter 2016 on May 2. Management will conduct a conference call at ...
04/25/16 08:20 AMCerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference - [at noodls] - Dr. Krasner to Present Phase 1b Results of CRLX101 in Combination with Weekly Paclitaxel in Relapsed Ovarian Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage ...
04/25/16 08:15 AM9:15 am Cerulean Pharma announces oral presentation of CRLx101 clinical data at Gynecologic Oncology 2016 Conference, combination of CRLX101 & weekly paclitaxel appears to be 'well-tolerated' in platinum-resistant ovarian cancer patients -
04/25/16 06:15 AMCerulean to Host First Quarter 2016 Conference Call on May 2 - [at noodls] - WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities ...
04/24/16 01:26 AMCerulean Pharma Inc's Stock Is Sell After Today's Huge Decline - CCH Daily News - Cerulean Pharma Inc's Stock Is Sell After Today's Huge DeclineCCH Daily NewsThe stock of Cerulean Pharma Inc (NASDAQ:CERU) is a huge mover today! The stock decreased 1.98% or $0.08 on April 22, hitting $3.97. About 516,990 shares traded hands or 61.47% up from the average. Cerulean Pharma Inc (NASDAQ:CERU) has ...
04/23/16 12:57 AMCerulean Pharma Inc (NASDAQ:CERU): We Are Up 18% In Just 2 Trading Sessions - Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term ...
04/21/16 10:30 PMCan Shares Of Cerulean Pharma Inc. (NASDAQ:CERU) Hit $9? - Investor Newswire - Can Shares Of Cerulean Pharma Inc. (NASDAQ:CERU) Hit $9?Investor NewswireThe Buy recommendations for Cerulean Pharma Inc. (NASDAQ:CERU) stock is 0, sell recommendations at 0 and hold recommendations count at 0. It boasts a total of 5 Strong Buy calls and 0 Strong Sell calls as of 2016-04-21. One month ago, the strong buy ...and more »
04/20/16 09:39 PMCerulean Pharma Inc. (CERU) Analyst Review - Risers & Fallers - The Vista VoiceCerulean Pharma Inc. (CERU) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Cerulean Pharma Inc. (CERU). According to the latest broker reports outstanding on Wednesday 20th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy ...Most Recent Update on Price Moves: Cerulean Pharma Inc. (NASDAQ:CERU) , Spectrum Pharmaceuticals, Inc ...Street UpdatesCerulean Pharma Soars 10% as Co to Show Avastin, CRLX101 Help Fight Ovarian Cancer (NASDAQ:CERU)Sonoran Weekly ReviewCerulean Pharma's (CERU) Outperform Rating Reaffirmed at WedbushThe Vista VoiceWeb Breaking News -Analyst Ratingsall 8 news articles »
04/20/16 10:04 AMWaltham's Cerulean gains on promising trial news from ovarian cancer drug -
About Cerulean Pharma

Cerulean Pharma logoCerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CERU
  • CUSIP:
Key Metrics:
  • Previous Close: $2.14
  • 50 Day Moving Average: $2.29
  • 200 Day Moving Average: $2.63
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $56.64M
  • Current Quarter EPS Consensus Estimate: $-1.80 EPS
Additional Links:
Cerulean Pharma (NASDAQ:CERU) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha